Leading electronic cigarette brand Intellicig has been accepted into one of the world's top centers for biomedical research.

To make their products the healthiest and cleanest on the market, Intellicig has established a laboratory at Manchester's Bioscience Incubator to perform their own clinical trials on their products.

Working in partnership with the University of Manchester Incubator Company (UMIC), Intellicig has access to state-of-the-art laboratories fully accredited for bioscience and biotech developments and in-house mentoring and professional services.

David Newns, Intellicig commercial director, said: "Being accepted into the UMIC programme is another positive step forward in the development of our products.

"We take quality control very seriously and our commitment to reinvestment will ensure that we are able to produce the safest and most reliable products on the market.

"Forming this partnership with UMIC will help us reach even higher standards and will also facilitate our clinical trials which are a prerequisite as far as Intellicig is concerned."

Intellicig has already invested heavily in producing their own brand of nicotine liquid 'e-liquid' right here in the UK, the only company currently doing so.

ECOpure has been achieved through intensive research, testing and stringent quality control and is distinct from their competitors, who use e-liquid imported from abroad containing unmonitored chemicals.

"Taking up residence in the 86,500 square feet UMIC laboratory and office complex located in the heart of Manchester's health corridor will enable us to further develop our nicotine solution," said David.

"Being affiliated with such an academically supportive company and gives our customers reassurance and will help to dispel any negativity surrounding electronic cigarettes."